Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease
The DOI matches its Crossref record; 55 of the 57 references it cites were found in a registry or an index.
Abstract
In contrast with the earlier stages and, in particular, the predementia stage, of Alzheimer's disease (AD), severe dementia is often neglected. However, the advanced stages of dementia are just as important as the earlier stages because of their frequency, their impact on the lives of patients and their caregivers, and their economic consequences. All patients with moderately severe to severe dementia must be evaluated for cognitive, functional, psychological and behavioural symptoms. Thorough and regular evaluation of patients in the advanced stages of the disease has the following objectives: improving patients' quality of life by encouraging use of their remaining capacities; setting up or modifying a care plan; playing a role in the follow-up of measures instituted; and documenting the natural history of the disease. Therapeutic trials with cholinesterase inhibitors and memantine have been conducted in patients with severe stages of AD. As a consequence, memantine has been approved by numerous drug agencies and donepezil has been approved by the US FDA for use in severe stages of the disease. However, it is important to note that at this stage of AD, and perhaps more than in any other, management must be global and multidisciplinary because of the expression of the disease, its complications and intercurrent disorders. Indeed, thorough knowledge by health professionals of the expression of all disease disorders and intercurrent disorders, and of their significance during…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies have consistently shown that proactive management of Alzheimer's and other dementias can improve the quality of life of affected individuals and their caregivers.[59][60][61]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [60]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Relatives of the Impaired Elderly: Correlates of Feelings of Burden
Zarit, S. H., Reever, K. E., & Bach-Peterson, J. (1980) · The Gerontologist · doi:10.1093/geront/20.6.649 · Cited by 5,810
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986
Progress in Development of the Index of ADL
Katz, S., Downs, T. D., Cash, H. R., & Grotz, R. C. (1970) · The Gerontologist · doi:10.1093/geront/10.1_part_1.20 · Cited by 4,118
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
A Description of Agitation in a Nursing Home
Cohen-mansfield, J., Marx, M. S., & Rosenthal, A. S. (1989) · Journal of Gerontology · doi:10.1093/geronj/44.3.m77 · Cited by 1,349
Research works printed but not linked: 7
- Eastwood, 1994, Int Psychiatry Today, 4, 8
- Gillette-Guyonnet, 2003, J Nutr Health Ageing, 7, 91
- Saxton, 1990, J Consult Clin Psychol, 3, 198
- Warshaw, 1997, Alzheimer Dis Assoc Disord, 11, 66
- Vellas, 2005, J Nutr Health Aging, 9, 330
- 2003, J Nutr Health Aging, 7, 304
- Ballard, 2006, Cochrane Database Syst Rev, &NA;, CD003476
Cited by
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
Metadata
- Authors
- Voisin, T., & Vellas, B.
- Affiliations
- Inserm (FR)
- Corresponding author
- Vellas, Bruno
- ORCID
- Vellas, Bruno
- Venue
- Drugs & Aging
- Published
- 2009
- Volume
- 26
- Issue
- 2
- Pages
- 135-144
- ISSN
- 1170-229X (ISSN-L)
- OpenAlex
- W2092173737
- Cited by
- 89
- References
- 57
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 8 · 2022: 8 · 2021: 6 · 2020: 6 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 6 · 2012: 5
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs & Aging (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- severe Alzheimer's disease, advanced dementia, cholinesterase inhibitors, memantine, donepezil, multidisciplinary care, behavioural symptoms, functional assessment, quality of life, natural history of dementia, dementia management
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Quality of Life, Caregivers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease. https://app.cochat.ai/papers/10.2165/0002512-200926020-00005
- The paper
- Voisin, T., & Vellas, B. (2009). Diagnosis and Treatment of Patients with Severe Alzheimer’s Disease. Drugs & Aging. https://doi.org/10.2165/0002512-200926020-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.